Last reviewed · How we verify

Omecamtiv Mecarbil Matrix F1 Formulation

Cytokinetics · Phase 2 active Small molecule

Omecamtiv Mecarbil Matrix F1 Formulation is a Small molecule drug developed by Cytokinetics. It is currently in Phase 2 development. Also known as: AMG 423, CK-1827452.

At a glance

Generic nameOmecamtiv Mecarbil Matrix F1 Formulation
Also known asAMG 423, CK-1827452
SponsorCytokinetics
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Omecamtiv Mecarbil Matrix F1 Formulation

What is Omecamtiv Mecarbil Matrix F1 Formulation?

Omecamtiv Mecarbil Matrix F1 Formulation is a Small molecule drug developed by Cytokinetics.

Who makes Omecamtiv Mecarbil Matrix F1 Formulation?

Omecamtiv Mecarbil Matrix F1 Formulation is developed by Cytokinetics (see full Cytokinetics pipeline at /company/cytokinetics).

Is Omecamtiv Mecarbil Matrix F1 Formulation also known as anything else?

Omecamtiv Mecarbil Matrix F1 Formulation is also known as AMG 423, CK-1827452.

What development phase is Omecamtiv Mecarbil Matrix F1 Formulation in?

Omecamtiv Mecarbil Matrix F1 Formulation is in Phase 2.

Related